5 of the Safest Ultra-High-Yield Dividend Stocks You Can Confidently Buy for 2026

Core Viewpoint - The article highlights five high-yield dividend stocks with yields ranging from 5.3% to 13.1%, which are positioned to provide significant income for investors in the upcoming year [1]. Group 1: Dividend Stocks Performance - Companies that consistently pay dividends tend to be profitable and provide a transparent long-term growth outlook, historically outperforming non-dividend stocks [2]. - A study by Hartford Funds and Ned Davis Research shows that dividend stocks have more than doubled the average annual return of non-payers (9.2% vs. 4.31%) over a 51-year period while being less volatile [3]. Group 2: Individual Stock Analysis - Sirius XM Holdings: Offers a yield of 5.27%, operates as a legal monopoly in satellite radio, and has a strong subscription-based revenue model [6][7][8]. The stock is valued at less than 7 times forward-year earnings, indicating a favorable investment opportunity [9]. - Enterprise Products Partners: Provides a yield of 6.78%, has increased its payout for 27 consecutive years, and operates a predictable cash flow model due to long-term fixed-fee contracts [10][11]. The stock is trading at less than 8 times forecast cash flow for 2026, presenting a value opportunity [13]. - Realty Income: Delivers a yield of 5.62%, pays dividends monthly, and has a strong track record of increasing payouts [15]. The company focuses on leasing to resilient businesses, and shares are valued at less than 13 times projected cash flow for 2026, offering a 19% discount to its historical average [16][18]. - PennantPark Floating Rate Capital: Features a yield of 13.09%, primarily invests in debt with a high weighted-average yield of 10.2% [20][21]. The company is trading at a 13% discount to its book value, indicating a potential value investment [23]. - Pfizer: Offers a yield of 6.83%, has seen a decline in share price, which has increased its dividend yield [25]. The company is expected to generate $62 billion in sales by 2025, with a strong oncology pipeline following its acquisition of Seagen [26][27]. Pfizer is valued at 8.4 times forward-year earnings, representing a 14% discount to its historical average [28].